Flag of the European Union EU Clinical Trials Register Help

Clinical trials for C2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    105 result(s) found for: C2. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2020-002537-15 Sponsor Protocol Number: R10933-10987-COV-2066 Start Date*: 2020-10-06
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-003126-25 Sponsor Protocol Number: MS201923-0001 Start Date*: 2012-09-27
    Sponsor Name:Merck KGaA
    Full Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
    Medical condition: cancer (malignant solid tumors)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001896-19 Sponsor Protocol Number: P2-IMU-838-MS Start Date*: 2018-12-17
    Sponsor Name:Immunic AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) DE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2005-004299-19 Sponsor Protocol Number: 1A/8655-5 Start Date*: 2005-10-26
    Sponsor Name:University Hospital Ostrava
    Full Title: New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation
    Medical condition: patient on standart immunusupresive therapy with cyclosporine A after renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002489-15 Sponsor Protocol Number: 380119 Start Date*: 2021-03-23
    Sponsor Name:Medinova AG
    Full Title: Comparative study of the efficacy and safety of vaginally applied Dequalinium Chloride (10 mg) and orally applied Metronidazole (2 x 500 mg) in the treatment of bacterial vaginosis
    Medical condition: Bacterial vaginosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10004055 Bacterial vaginosis PT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021642-22 Sponsor Protocol Number: VR1114693 Start Date*: 2011-04-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part study to investigate the pharmacokinetics and pharmacodynamics of SB705498, a TRPV1 antagonist, in cough. Part A: an open label study in healthy subjects to determine the exposure to SB-...
    Medical condition: Chronic cough
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-006162-33 Sponsor Protocol Number: ML 19835 Start Date*: 2006-07-03
    Sponsor Name:ROCHE
    Full Title: Relationships between pharmacokinetic and pharmacodynamic strategies for assessment of the risks for acute rejection and side effects of mofetil mycophenolate
    Medical condition: Kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    6.1 10023439 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001011-21 Sponsor Protocol Number: LITA-001 Start Date*: 2016-06-01
    Sponsor Name:Litaphar S.L.
    Full Title: A prospesctive, open-label 12-weeks treatment study to determine the effect of tadalafil 5 mg on clitoral blood flow in menopausal and hipertensive women with sexual interest and arousal disorder
    Medical condition: Sexual interest and arousal disorder in menopausal and hierpertensive women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000207-36 Sponsor Protocol Number: 275AS101 Start Date*: 2020-11-18
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 ...
    Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10052653 Amyotrophic lateral sclerosis gene carrier PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002266-10 Sponsor Protocol Number: TXH-VHC04 Start Date*: 2005-11-11
    Sponsor Name:Dr. Evaristo Varo Pérez
    Full Title: Estudio para comparar la evolución de la hepatitis C con ciclosporina C2 frente a tacrolimus en receptores de trasplante hepático de novo virus C positivos. Study to compare hepatitis C evolution ...
    Medical condition: Trasplante hepático
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001290-25 Sponsor Protocol Number: CERL080A2415 Start Date*: 2005-09-14
    Sponsor Name:St Vincent's Hospital
    Full Title: A 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing de Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclospori...
    Medical condition: Heart-Lung, bilateral lung and single lung transplant recipients ICD Classification: K01-K01.9, E53.9+Z94.1, E53.9+Z94.2, E53.9+Z94.3
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001671-30 Sponsor Protocol Number: 2013-TL-MEL-Th Start Date*: 2015-07-31
    Sponsor Name:Centre Eugène Marquis
    Full Title: Evaluation of cobimetinib + vemurafenib combination treatment in patients with brain metastasis BRAFV600 mutated cutaneous melanoma
    Medical condition: Patients with brain metastasis (BM) from BRAFV600-mutated cutaneous melanoma. Patients will be enrolled into three cohorts: A. Neurologically asymptomatic patients who have not received prior loc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000222-22 Sponsor Protocol Number: 2004/045 Start Date*: 2005-04-25
    Sponsor Name:OLV-ziekenhuis
    Full Title: Prospective Open Single-Centre Study on the Effect of Initiation of RAD and CNI minimalisation on renal function in heart transplant patients
    Medical condition: heart transplant patients with impaired renal function under treatment of CNI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001536-98 Sponsor Protocol Number: PREPSARS Start Date*: 2020-04-18
    Sponsor Name:HOSPITAL UNIVERSITARI MÚTUA TERRASSA
    Full Title: Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection.
    Medical condition: COVID-19 infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004998-32 Sponsor Protocol Number: ARGX-117-2003 Start Date*: 2022-12-19
    Sponsor Name:argenx BV
    Full Title: A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Mult...
    Medical condition: Multifocal Motor Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001517-32 Sponsor Protocol Number: K-877-201 Start Date*: 2013-10-02
    Sponsor Name:Kowa Research Europe
    Full Title: A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels
    Medical condition: dyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004845-25 Sponsor Protocol Number: BO29561 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and ritu...
    Medical condition: Follicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001480-42 Sponsor Protocol Number: MIPO3801011 Start Date*: 2012-04-26
    Sponsor Name:Genzyme Corporation and its Affiliates
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemi...
    Medical condition: Heterozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) BE (Completed) GB (Completed) FR (Completed) HU (Completed) DE (Completed) CZ (Completed) GR (Completed) IT (Completed) PL (Completed) SK (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004399-11 Sponsor Protocol Number: 380204 Start Date*: 2006-12-11
    Sponsor Name:Medinova AG
    Full Title: The Efficacy of 10 mg Dequalinium Chloride (Fluomizin®) in the Local Treatment of Aerobic Bacterial Vaginal Infections in Comparison to Placebo
    Medical condition: Aerobic Bacterial Vaginal Infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046914 Vaginal infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004189-27 Sponsor Protocol Number: WO30085 Start Date*: 2016-10-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS W...
    Medical condition: Unresectable locally advanced or metastatic breast cancer (MBC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 17:16:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA